ArticleMolecular and cellular biology2011
Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer.
Article in Molecular and cellular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Phosphoproteomic Landscape of HDLBP: Insights into Function and Disease Associations.International journal of molecular sciences · 2026Article
- New insights into tuberous sclerosis complex: from structure to pathogenesis.Frontiers in cell and developmental biology · 2025Review
- The high-density lipoprotein binding protein HDLBP is an unusual RNA-binding protein with multiple roles in cancer and disease.RNA biology · 2024Review
- Eltrombopag Inhibits Metastasis in Breast Carcinoma by Targeting HuR Protein.International journal of molecular sciences · 2023Article
- HDLBP binds ER-targeted mRNAs by multivalent interactions to promote protein synthesis of transmembrane and secreted proteins.Nature communications · 2022Article
- Association of mammographic density with blood DNA methylation.Epigenetics · 2022Article
- Regulation of closely juxtaposed proto-oncogeneRNA (New York, N.Y.) · 2021Article
- Autism-Associated Vigilin Depletion Impairs DNA Damage Repair.Molecular and cellular biology · 2021Article
- Phenotype of vigilin expressing breast cancer cells binding to the 69 nt 3'UTR element in CSF-1R mRNA.Translational oncology · 2019Article
- RNA Binding Protein Vigilin Collaborates with miRNAs To Regulate Gene Expression forG3 (Bethesda, Md.) · 2017Article
- Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.Neoplasia (New York, N.Y.) · 2016Review
- The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation.Nature communications · 2016Article
- Human somatic cell mutagenesis creates genetically tractable sarcomas.Nature genetics · 2014Article
- Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.Experimental biology and medicine (Maywood, N.J.) · 2014Article
- Nucleolin mediates microRNA-directed CSF-1 mRNA deadenylation but increases translation of CSF-1 mRNA.Molecular & cellular proteomics : MCP · 2013Article
- Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.International journal of molecular sciences · 2013Review
- Characterization of the distal polyadenylation site of the ß-adducin (Add2) pre-mRNA.PloS one · 2013Article
- Identification of RNA-protein interaction networks involved in the norovirus life cycle.Journal of virology · 2012Article
- Role of RNA binding protein HuR in ductal carcinoma in situ of the breast.The Journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
cis-acting elements found in 3'-untranslated regions (UTRs) are regulatory signals determining mRNA stability and translational efficiency. By binding a novel non-AU-rich 69-nucleotide (nt) c-fms 3' UTR sequence, we previously identified HuR as a promoter of c-fms proto-oncogene mRNA. We now identify the 69-nt c-fms mRNA 3' UTR sequence as a cellular vigilin target through which vigilin inhibits the expression of c-fms mRNA and protein. Altering association of either vigilin or HuR with c-fms mRNA in vivo reciprocally affected mRNA association with the other protein. Mechanistic studies show that vigilin decreased c-fms mRNA stability. Furthermore, vigilin inhibited c-fms translation. Vigilin suppresses while HuR encourages cellular motility and invasion of breast cancer cells. In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.